Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma ; volume:11 ; number:2 ; year:2021 ; pages:174-177 ; extent:4
Liver cancer ; 11, Heft 2 (2021), 174-177 (gesamt 4)

Urheber
Johira, Yusuke
Kawaoka, Tomokazu
Kosaka, Masanari
Shirane, Yuki
Miura, Ryoichi
Murakami, Serami
Yano, Shigeki
Amioka, Kei
Naruto, Kensuke
Ando, Yuwa
Kosaka, Yumi
Kodama, Kenichiro
Uchikawa, Shinsuke
Fujino, Hatsue
Ono, Atsushi
Nakahara, Takashi
Murakami, Eisuke
Okamoto, Wataru
Yamauchi, Masami
Imamura, Michio
Sentani, Kazuhiro
Oue, Naohide
Arihiro, Koji
Kuroda, Shintaro
Kobayashi, Tsuyoshi
Ohdan, Hideki
Chayama, Kazuaki
Aikata, Hiroshi

DOI
10.1159/000520898
URN
urn:nbn:de:101:1-2022042100201603571956
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 05:35 UTC

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Johira, Yusuke
  • Kawaoka, Tomokazu
  • Kosaka, Masanari
  • Shirane, Yuki
  • Miura, Ryoichi
  • Murakami, Serami
  • Yano, Shigeki
  • Amioka, Kei
  • Naruto, Kensuke
  • Ando, Yuwa
  • Kosaka, Yumi
  • Kodama, Kenichiro
  • Uchikawa, Shinsuke
  • Fujino, Hatsue
  • Ono, Atsushi
  • Nakahara, Takashi
  • Murakami, Eisuke
  • Okamoto, Wataru
  • Yamauchi, Masami
  • Imamura, Michio
  • Sentani, Kazuhiro
  • Oue, Naohide
  • Arihiro, Koji
  • Kuroda, Shintaro
  • Kobayashi, Tsuyoshi
  • Ohdan, Hideki
  • Chayama, Kazuaki
  • Aikata, Hiroshi

Ähnliche Objekte (12)

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort

Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report

Significant response to atezolizumab plus bevacizumab treatment in unresectable hepatocellular carcinoma with major portal vein tumor thrombus: a case report

Verbundene Objekte